Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine

Vaccine

Volumn 19, Issue 15-16, 2001, Pages 2071-2079

  Hagiwar, Yukari ^a,b   Tsuji, Takao ^c   Iwasaki, Takuya ^a   Kadowaki, Shin etsu ^a   Asanuma, Hideki ^a   Chen, Ze ^a   Komase, Katsuhiro ^b   Suzuki, Yujiro ^b   Aizawa, Chikara ^b   Kurata, Takeshi ^a   Tamura, Shin Ichi ^a  

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b KITASATO INSTITUTE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adjuvant; Mucosal immunity; Mutant heat labile enterotoxin; Nasal influenza vaccine

Indexed keywords

ESCHERICHIA COLI ENTEROTOXIN; IMMUNOGLOBULIN E; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LT H44A; UNCLASSIFIED DRUG;

ADRENAL CELL; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; GUINEA PIG; IN VITRO STUDY; INFLUENZA; INFLUENZA VIRUS; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TOXICITY TESTING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AMINO ACID SUBSTITUTION; ANIMALS; ANTIBODIES, VIRAL; BACTERIAL TOXINS; BODY WEIGHT; CELL LINE; ENTEROTOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN E; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; NASAL MUCOSA; POINT MUTATION; SAFETY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0035961457     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00414-X     Document Type: Article

References (47)

1. Amino acid homology between cholera toxin and Escherichia coli heat-labile toxin
2. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli
3. Structure and function of cholera toxin and related Escherichia coli enterotoxin
4. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen
5. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens
6. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein anitgens
7. Effect of cholera toxin adjuvant on IgE antibody response to orally or nasally administered ovalbumin
8. Production of IgE antibody and allergic sensitization of intestinal and peripheral tissues after oral immunization with protein Ag and cholera toxin
9. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-adsorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant
10. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response
11. Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit
12. Construction of a plasmid for expression of foreign epitopes as fusion proteins with subunit B of Escherichia coli heat-labile enterotoxin
13. Cholera toxin B-subunit gene fusion: Structural and functional analysis of the chimeric protein
14. Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin
15. Synergistic action of cholera toxin B subunit (and E. coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine
16. Escherichia coli heat labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine
17. Chorela toxin as a mucosal adjuvant. Glutaraldehyde treatment dissociates adjuvanticity from toxicity
18. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvant
19. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
20. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
21. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
22. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine
23. Superior cross-protective effect of nasal vaccination to subcutaneous inoculation with influenza HA vaccine
24. Cross-protection against influenza A virus infection by passively transferred respiratory tract IgA antibodies to different hemagglutinin molecules
25. Cross-protection against influenza virus infection afforded by trivalent inactivated vaccines inoculated intranasally with cholera toxin B subunit
26. Intranasal immunization with influenza vaccine
27. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
28. Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers
29. Mutants of cholera toxin as an effective and safe adjuvant for nasal influenza vaccine
30. Site-specific mutagenesis of the catalytic subunit of cholera toxin: Substituting lysine for arginine 7 causes loss of activity
31. Histidine-44 of the A subunit of Escherichia coli enterotoxin is involved in its enzymatic and biological activities
32. Comparison of serologic and febrile responses in humans to vaccination with influenza A viruses or their hemagglutinin
33. Simple method of purification of Escherichia coli heat-labile enterotoxin and cholera toxin using immobilized galactose
34. A sensitive substrate for the clotting enzyme in horseshoe crab hemocytes
35. Detection of heat-labile Escherichia coli enterotoxin with the use of adrenal cells in tissue culture
36. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein
37. Mucosal adjuvant effect of cholera toxin in mice results from induction of helper 2 (Th2) cells and IL-4
38. Measurement of antigen-specific mouse IgE by a fluorometric reverse (IgE-capture) ELISA
39. Recognition of cloned influenza virus hemagglutinin gene products by cytotoxic T lymphocytes
40. Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice
41. Fluid accumulation in mouse ligated intestine inoculated with Clostridium perfringens enterotoxin
42. Purification and partial characterization of heat-stable enterotoxin of enterotoxigenic Escherichia coli
43. In vivo proliferation of naïve and memory influenza specific CD8+ T cells
44. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
45. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity form ADP-ribosyltransferase activity
46. A genetically detoxified derivative of heat-labile Escherichia coli enterotoxin induces neutralizing antibodies against the A subunit
47. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity